The newly issued patent expands and reinforces Autonomix's intellectual property estate related to real-time nerve sensing, mapping, physiological monitoring, and feedback-guided neuromodulation technologies. The patented systems and methods are designed to enable more precise targeting of autonomic nerves associated with a variety of chronic disease states, including hypertension, chronic heart failure, chronic renal failure, metabolic disorders, and other conditions linked to autonomic nervous system dysfunction and renal sympathetic nerve hyperactivity.

Unlike conventional denervation approaches that rely primarily on anatomical landmarks, the patented technology incorporates sensing-enabled devices capable of detecting neural and physiological responses in real time. This closed-loop approach may enable physicians to locate neural targets more accurately, assess treatment effects during therapy delivery, and evaluate procedural success through objective physiological feedback.

Corresponding patents covering related inventions have previously been issued in the United States and Europe, reinforcing Autonomix's intellectual property position across major commercial markets.